EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn’s Disease and Ulcerative Colitis

Andreja Ocepek iD, Nikolaus Molinari, Petra Maček, Jan Zmazek iD, Sara Nikolić iD

Medicina · 10.04.2026 · 62 (4) · 722

DOI: 10.3390/medicina62040722 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina, online erschienen am 10.04.2026. Verfasst von Andreja Ocepek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of gastroenterology, University Medical Centre Maribor, Ljubljanska 5, 2000 Maribor, Slovenia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Crohn Disease, Colitis, Ulcerative, Decision Support Systems, Clinical. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: The vedolizumab clinical decision support tool (VDZ-CDST) was developed to predict treatment outcomes in inflammatory bowel disease (IBD). While validated in clinical trial and consortium settings, its real-world performance remains less clear. The aim of our study was to evaluate the predictive value of pre-treatment CDST stratification for clinical and endoscopic outcomes and treatment persistence in real-world VDZ-treated IBD patients. Materials and Methods: We conducted a retrospective analysis of consecutive IBD patients initiating vedolizumab therapy, stratified by CDST risk groups. Clinical remission (CR) and corticosteroid-free remission (CSFR) at weeks 14 and 52 were assessed using PRO-2 in both Crohn’s disease (CD) and ulcerative colitis (UC). Endoscopic outcomes and treatment persistence were also evaluated.

Results

129 IBD patients, 57 with CD and 72 with UC, treated with vedolizumab were retrospectively stratified according to VDZ-CDST. In CD at week 52 the differences in CSFR between CDST groups were statistically significant (p = 0.04). A statistically significant association (p < 0.001) was also observed between CDST groups and endoscopic activity (EA) at follow-up endoscopy. In the low-probability group 69.2% showed persistent EA, whereas in the high-probability group 68.8% achieved endoscopic remission (ER). We also found significant differences (p = 0.004 and p < 0.001, respectively) in treatment persistence between CDST groups in CD. VDZ discontinuation rates were 76.9%, 28.6%, and 6.3% in the low-, intermediate-, and high-response groups, respectively. In UC, no predictive association was observed for either clinical or endoscopic outcomes nor treatment persistence; however, we observed relatively high remission rates despite CDST-based stratification.

Conclusions

Although the VDZ-CDST failed to predict CR measured by PRO-2 in real-world IBD patients, it demonstrated meaningful associations with long-term CSFR, endoscopic outcomes and treatment persistence in Crohn’s disease. These findings support its role as a supportive tool in therapeutic decision-making, particularly when objective outcomes such as mucosal healing are prioritized. Prospective multicentre studies incorporating biomarkers and pharmacokinetic data are needed to refine VDZ-CDST for broader clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCrohn DiseaseColitis, UlcerativeDecision Support Systems, ClinicalHumansFemaleRetrospective StudiesMaleAdultMiddle AgedGastrointestinal AgentsCohort StudiesTreatment OutcomePredictive Value of Tests

Stichwörter der Autor:innen

Crohn’s diseaseclinical decision support toolulcerative colitisvedolizumab

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • Department of gastroenterology, University Medical Centre Maribor, Ljubljanska 5, 2000 Maribor, Slovenia.
  • Medical Faculty, University of Maribor, Taborska 8, 2000 Maribor, Slovenia.
  • Faculty of Natural Sciences and Mathematics, University of Maribor, Koroška 160, 2000 Maribor, Slovenia.

ORCID-Profile: Andreja Ocepek, Jan Zmazek, Sara Nikolić

Zitieren

APA

Ocepek, A., Molinari, N., Maček, P., Zmazek, J., & Nikolić, S. (2026). Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn’s Disease and Ulcerative Colitis. Medicina, 62(4), 722. https://doi.org/10.3390/medicina62040722

Vancouver

Ocepek A, Molinari N, Maček P, Zmazek J, Nikolić S. Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn’s Disease and Ulcerative Colitis. Medicina. 2026;62(4):722. doi:10.3390/medicina62040722

BibTeX
@article{Ocepek2026,
  author = {Ocepek, Andreja and Molinari, Nikolaus and Maček, Petra and Zmazek, Jan and Nikolić, Sara},
  title = {Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn’s Disease and Ulcerative Colitis},
  journal = {Medicina},
  year = {2026},
  volume = {62},
  number = {4},
  pages = {722},
  doi = {10.3390/medicina62040722}
}
Kostenlos starten →